Amanita muscaria is the red-and-white spotted mushroom, sold as gummies, capsules, and tinctures for sleep, calm, and mood. Its two main compounds pull in opposite directions — one calms the brain, the other excites it — and drying or cooking decides which dominates. No controlled human study exists for any outcome; sedation, nausea, unsteadiness, and confusion are reliably documented. (Full Review)

Protocol

Microdose pattern

0.1–1 g dried equivalent

Small daily or alternate-day doses of dried cap or extract, below any perceptible psychoactive threshold. There is no protocol validated by any clinical trial.

Time of day

Evening, 1–2 h before sleep

Aligns the sedative peak with sleep onset and confines impairment to sleep hours. Morning dosing is promoted, but that claim has no supporting data.

Single versus split dosing

Single dose, no splitting

Single dosing is standard and is the safer choice. Splitting is discouraged: the second dose lands while the first is still near peak.

Time to effect

Onset

30–120 minutes

Total duration of effect is 4 to 10 hours.

Peak

2–3 hours

There is no loading period and no delayed onset of the kind seen with antidepressants.

Claimed cumulative benefit

2–4 weeks

Claimed by proponents; also the window in which expectation effects are strongest, and no controlled data separate the two.

Benefits

Medium: Dose-dependent sedation and reduction in arousal

Low: Self-reported sleep onset and continuity; stress and depressive symptoms; analgesia and topical symptom relief

Speculative: Peripheral nerve repair; antimicrobial, antioxidant, and antiproliferative activity; substitution for alcohol or prescription sedatives

Contraindications

Alcohol

Barbiturates (phenobarbital), sodium oxybate, baclofen, general anaesthetics (propofol)

Pregnancy and breastfeeding

Seizure disorder or prior unprovoked seizure

Psychotic-spectrum diagnosis or first-degree family history

Kidney disease stage 3b or worse (eGFR below 45)

Advanced liver disease (Child-Pugh B or C)

Untreated obstructive sleep apnea (15 or more events per hour)

Sedative, alcohol, or opioid use disorder

Symptomatic bradyarrhythmia, resting heart rate below 50 bpm, second- or third-degree heart block

Moderate-to-severe asthma

Age under 18 or over 75

Driving, machinery, dependent care, or on call within 24 hours

Key Interactions

Benzodiazepines and Z-drugs (diazepam, lorazepam; zolpidem, zopiclone)

Opioids (oxycodone, morphine, tramadol)

Gabapentinoids (gabapentin, pregabalin)

Sedating antihistamines (diphenhydramine, doxylamine)

Dextromethorphan and alcohol-containing cough preparations

Anticholinergic medication (atropine, oxybutynin, scopolamine, amitriptyline)

Sedative and calming supplements (GABA, glycine, kava, valerian, phenibut, ashwagandha, L-Theanine, cannabidiol)

Melatonin

Other interventions: sauna, cold exposure, fasting

Risk & Side Effects

High: Acute neurotoxic intoxication syndrome; gastrointestinal distress

Medium: Seizures and myoclonic jerking; cholinergic symptoms; unpredictable potency, mislabelling, and adulteration; prolonged delirium and anterograde amnesia; misidentification when foraging

Low: Heavy metal and radionuclide accumulation in wild specimens; next-day impairment; impaired driving and safety-critical activity

Speculative: Tolerance, receptor adaptation, and withdrawal; cumulative excitotoxic injury; degradation of sleep architecture with chronic use

Monitoring

Marker	Target	Why
Estimated glomerular filtration rate (eGFR)	≥ 90 mL/min/1.73 m²	Governs clearance and exposure duration
Serum creatinine	0.6–1.0 mg/dL (women), 0.7–1.2 mg/dL (men)	Direct input to filtration estimates
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)	ALT < 25 U/L (men), < 20 U/L (women); AST < 25 U/L	Detects hepatic injury or adulterants
Complete blood count (CBC) with differential	Within reference range, no trend	Screens for marrow, immune, and anaemia effects
Blood cadmium	< 0.5 µg/L	This species actively accumulates cadmium
Blood mercury	< 3.0 µg/L	Documented bioaccumulation relative to soil
Blood lead	< 1.0 µg/dL	Common co-contaminant of wild-harvested fungi
Resting heart rate	50–70 bpm, stable versus baseline	Screens for muscarinic bradycardia
Overnight heart rate variability and deep sleep minutes	Individual baseline, tracked as trend	Objective readout of the claimed sleep benefit

Cadence: Baseline before the first dose; kidney and liver at 4 weeks, then every 3 to 6 months; blood count at 3 months, then annually; heavy metals at 6 months, then annually.

Qualitative Assessment

Sleep quality and continuity: restfulness, awakenings, time to fall asleep
Next-day cognitive clarity: whether the first two hours feel dull or normal
Daytime energy and motivation: tracked at a fixed time each afternoon
Baseline anxiety and perceived stress: a 0-to-10 rating at a consistent time
Pain intensity, where pain was the reason for use: rated at the same time daily
Any escalation in the amount needed: the earliest observable sign of tolerance
Nausea, headache, sweating, salivation, or unusual muscle twitching: inadequate decarboxylation or a high-muscarine batch

Amanita muscaria for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment